The American pharmaceutical company Moderna, which has launched a vaccine during the new crown epidemic, earlierAnnounced the start of Phase I and Phase II clinical trials of influenza vaccines that are also mRNA technology, Injected the vaccine into the body of the first volunteer tester. This vaccine is called “mRNA-1010” and is designed to be effective against the four most common influenza virus strains, A H1N1, A H3N2, B Yamagata, and B Victoria. The initial test will first ensure its safety, reactogenicity and immunity. Originality.
According to WHO data, these four virus strains will produce 3 to 5 million severe cases each year, and cause about 650,000 deaths due to respiratory-related diseases. The existing flu vaccine is about 40% to 60% effective, and Modena hopes that their new vaccine will have a much higher effect than the existing vaccine. Modena said that the combined respiratory vaccine is an important pillar of its mRNA vaccine program. They hope to mix a variety of mRNA vaccines including influenza, SARS-CoV-2 (new coronavirus) and human respiratory syncytial virus as needed. People can spend the whole winter safely after an injection in the fall.
The characteristic of the mRNA vaccine is to allow the body cells to produce proteins that look similar to the virus on their own, and then the immune system recognizes them to produce antibodies. Compared with the inactivated virus, it is safer, and it is not easy to fail due to the mutation of the virus; compared with the adenovirus vector vaccine, it has less negative effects. In this new crown epidemic, mRNA technology vaccines have achieved dazzling results in both efficacy and resistance to variants. It can be imagined that in the future it will become a weapon against rapidly mutating viruses, and even have the opportunity to develop vaccines such as malaria and HIV. basis.